CRISPR Therapeutics AG (CRSP) Current Leases (2019 - 2026)

CRISPR Therapeutics AG has disclosed Current Leases across 8 years of filings, most recently posting $18.6 million for Q2 2026.

• In Q2 2026, Current Leases rose 3.43% year-over-year to $18.6 million; the TTM figure through Jun 2026 stood at $18.6 million (up 3.43% YoY), while the FY2025 annual figure was $18.6 million, up 7.46% from the prior year.
• Current Leases came in at $18.6 million for Q2 2026 at CRISPR Therapeutics AG, roughly flat from $18.6 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $18.6 million in Q2 2026 to a low of $8.3 million in Q2 2022.
• Average Current Leases over 5 years is $15.8 million, with a median of $16.2 million recorded in 2024.
• Year-over-year, Current Leases plunged 47.92% in 2022 and jumped 79.42% in 2023.
• Over 5 years, Current Leases stood at $15.8 million in 2022, then decreased by 1.37% to $15.6 million in 2023, then rose by 10.64% to $17.3 million in 2024, then grew by 7.46% to $18.6 million in 2025, then advanced by 0.37% to $18.6 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $18.6 million in Q2 2026, $18.6 million in Q1 2026, and $18.6 million in Q4 2025.